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Compliance is a key factor in the maintenance treatment of bipolar disorder. This noninterventional study was
conducted to explore factors associated with higher levels of compliance in bipolar patients, all treated in routine
clinical settings. Bipolar outpatients (Clinical Global Impression of Severity score ≤3) who had been stabilized with
olanzapine mono- or combination therapy for ≥4 weeks were enrolled in the study. Compliance to medication was
assessed at baseline and after 3, 6, 9, 12, 18, and 24 months by a physician-rated, 4-point categorical scale using the
following classification: noncompliant (patients being compliant to treatment schedule less than 20% of the time) and
low (20% to 59% of the time), moderate (60% to 79% of the time), and high (≥80% of the time) levels of compliance.
Both baseline and post-baseline factors were used in a generalized estimating equations (GEE) model to predict the
likelihood of high compliance. Of 891 eligible patients, 657 patients completed the 24-month observation period.
High levels of compliance (≥80%) were observed in 67% of patients at baseline, increasing to 80% in study completers.
High compliance at baseline was identified as a strong predictor of compliance during study participation (odds
ratio (OR) = 6.9, 95% confidence interval (CI) = 5.0 to 9.5, p < 0.001). Factors associated with high compliance
during the study (GEE model) included greater life satisfaction (p = 0.002), better insight into illness (p < 0.001),
less work impairment (p = 0.007), and fewer days of inpatient care (p = 0.002). Compliance ratings varied by country
(p < 0.001) and duration of post-baseline treatment (p = 0.014). In conclusion, a number of clinical, functional, and
social factors were identified as predictors of compliance in patients with bipolar disorder. As compliance is crucial for
the long-term management of these patients, more attention should be directed towards compliance itself and factors
associated with compliance levels in everyday treatment settings.
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Compliance with pharmacological treatment is crucial
for response to medication and for long-term outcome
in any chronic medical condition (Haynes et al. 2002).
Compliance is usually higher in patients with acute illness
compared to patients with chronic disease, dropping
substantially after the first 6 months of treatment (Cramer
et al. 2003; Jackevicius et al. 2002). Despite the great* Correspondence: alexandra.kutzelnigg@meduniwien.ac.at
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ment regimens, patients with chronic mental illness
may frequently face more and specific difficulties in
being compliant compared to nonpsychiatric patients,
mainly due to a lack of insight, cognitive deficits, and
(dis)beliefs regarding the efficacy and safety profiles of
medication (Cramer and Rosenheck 1998; Osterberg
and Blaschke 2005; Pompili et al. 2013; Zygmunt et al.
2002). Noncompliance is usually difficult for clinicians
to detect and is thus underestimated in routine clinical
settings. However, it is strongly related to relevant clinical
outcomes such as relapse, (re)hospitalization, and suicideis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and bipolar disorder (Velligan et al. 2009). Furthermore,
noncompliance in patients with severe psychiatric illness
may have a substantial economic impact (Murray and
Lopez 1996; Sun et al. 2007).
Bipolar disorder is a common and often severe mental
illness with a lifetime prevalence of 1% to 3% (Judd and
Akiskal 2003; Regeer et al. 2004), which is associated with
a high risk for relapse (Li et al. 2014; Sharma et al. 2014;
Simhandl et al. 2014). Noncompliance with medication
has been frequently reported for bipolar patients, with a
reported incidence ranging from 20% to 60% (Adams and
Scott 2000; Colom and Vieta 2004; Gonzalez-Pinto et al.
2006). Several pharmacological treatment strategies have
been proposed for relapse prevention in patients with
bipolar disorder (Beynon et al. 2009) such as mood sta-
bilizers (Goodwin et al. 2003; Grunze et al. 2009) and,
according to more recent guidelines, second-generation
antipsychotics (Goodwin 2009; Grunze et al. 2009, 2010;
Yatham et al. 2013; Hirschfield 2014). Olanzapine is con-
sidered as first-line treatment for bipolar I disorder for
both acute episodes and relapse prevention (Grunze et al.
2009; Yatham et al. 2006) and has been systematically
studied in a large number of studies as monotherapy or in
combination with mood stabilizers and antidepressants,
such as fluoxetine, in all of these indications (Baker et al.
2003; Tohen et al. 1999, 2002, 2003, 2005, 2006).
Although the efficacy, safety, and tolerability of psy-
chopharmacological agents used to treat bipolar patients
have been widely evaluated (Beynon et al. 2009), the
current study is the first to evaluate compliance as the
primary outcome in long-term, routine treatment settings
and within a large patient population. The aims of the
study were to determine factors associated with better
compliance in patients with bipolar disorder stabilized on
olanzapine and to assess whether there was a difference in
compliance between patients stabilized on olanzapine
monotherapy and those stabilized on combination therapy.
The assessment of compliance was prioritized in our
study, as it might be one important factor contributing to
the lack of generalizability of clinical trial data and can be




This prospective, noninterventional, 24-month observa-
tional study (study code F1D-OE-B015) was conducted
to address the need for further information regarding
compliance in patients receiving long-term treatment for
bipolar disorder. Stable bipolar outpatients were recruited
from January 2005 to December 2006 in six countries
(Austria, Romania, Hungary, Korea, Taiwan, and Mexico).
The study protocol was acknowledged or approved by therelevant ethics committees. All patients and/or their au-
thorized legal representatives provided written informed
consent before screening. Treatment was prescribed in a
standard-of-care setting at the discretion of the treating
psychiatrist and was not provided by the sponsor during
or after participation in the study. Treatment changes, as
well as discontinuation of medication at any time after
baseline, were permitted and did not lead to discontinua-
tion of the respective patients. Concomitant medication at
any point in time and for any duration of treatment
during study participation was also allowed in order to
reflect routine clinical settings.
Patients
To maximize generalizability and in line with the obser-
vational design of the study, minimal patient eligibility
criteria were applied. Patients were enrolled at the dis-
cretion of their psychiatrist if all four conditions were
satisfied: (1) presented within the standard course of care
and were seen in an outpatient setting for the long-term
treatment of bipolar disorder, (2) had received olanzapine
oral medication alone or in combination with a mood
stabilizer for the treatment of bipolar disorder for at least
4 weeks before study entry and were in stable psychiatric
condition at screening (Clinical Global Impression of
Severity (CGI-S) score (Guy 1976) ≤3), (3) were at least
18 years of age, and (4) were not currently participating in
any other clinical trial with an interventional design. Data
were collected during the normal course of patient care at
the baseline visit and at routine follow-up visits, which
took place at approximately 3, 6, 9, 12, 18, and 24 months
thereafter.
Measures
As the study was designed to reflect everyday clinical
treatment settings, only measures, which are also com-
monly used in routine clinical care, were administered.
No specific diagnostic instruments were used to screen
for bipolar disorder, but physicians were asked to establish
the diagnosis according to their routine clinical approach.
Patients were further diagnosed as having bipolar I or
bipolar II disorder, as suffering from rapid cycling or not,
and as having a current manic/hypomanic or depressive
episode. The presence or absence of psychotic symptoms
during the current episode was also assessed. Besides
differential diagnosis, data on sex, age, race, education
status, psychiatric and treatment history (including rec-
ord of suicide attempts), and height were collected at
baseline to characterize the patient sample and detect
initial differences between groups. The following variables
were collected at baseline and at each study follow-up
visit: (1) treatment regimen(s), duration of treatment, and
level of compliance, (2) patient attitude to medication, (3)
disease severity, (4) medical resource use, (5) functional
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(8) quality of life, (9) comorbidities and concomitant
medication, and (10) weight. These variables were
assessed as follows.
(1) The main outcome measure was compliance with
the prescribed treatment regimen. This was evaluated
subjectively by the treating psychiatrist by assigning the
patients' compliance level to one of the four following
categories: high (patients being compliant with the
prescribed medication, appointments, and all other
interventions 80% to 100% of the time), moderate
(patients being compliant with all aspects of treatment
60% to 79% of the time), low (patients being compliant
20% to 59% of the time), and noncompliant (patients
being compliant <20% of the time). (2) In addition, the
Drug Attitude Inventory - short version (DAI-10) (Awad
1993) was used to measure patients' attitude towards
medication. Higher scores on the scale denote more
affirmative attitudes towards medication. (3) Disease
severity was measured by the CGI-S. (4) Information
on medical resource use related to bipolar disorder was
captured in a short questionnaire by quantifying the
number of outpatient consultations, number of inpatient
admissions, number of days spent in an inpatient facility,
and number of days on sick leave. (5) Functional status
was assessed by the physicians using a short categorical
questionnaire to capture the number of social activities
(with categories from 0 to ≥5), level of current work
activity (categories: unable to work, unemployed, retired,
student, housekeeping, sheltered program, volunteer
work, working for pay), impairment in work activities
(categories: unable to work due to mental illness, severe,
moderate, or no impairment), and satisfaction with life
(categories: very dissatisfied, dissatisfied, neither satisfied
nor dissatisfied, satisfied, very satisfied). (6) Relapse status
was determined as per the investigator's clinical assess-
ment (based on exacerbation of acute symptomatology,
hospitalization, etc.) and captured directly on the data
collection form using questions with a simple ‘yes’ or
‘no’ answer and in case of a relapse the date when
relapse was first noticed. (7) A 5-point categorical scale
was used to record the strength of the patient-physician
relationship (categories: poor, fair, good, very good,
excellent), as well as the patient's insight into illness
(categories: none, low, medium, moderate, high). (8)
Patient quality of life was assessed by the European
Quality of Life instrument-5 dimensions (EQ-5D) (The
EuroQol Group 1990), which consists of a patient-rated
five-dimension questionnaire and a visual analog scale
(VAS). (9) Comorbidities, use of concomitant medication,
and tolerability (expressed as the presence of side effects
judged to be associated with the patient's condition/
treatment) during the 4 weeks before baseline and since
the last visit, respectively, were captured.Statistical methods
The sample size calculation was based on the assumptions
of 80% completion rates, 30% of patients receiving mono-
therapy, 70% receiving polytherapy, and corresponding
compliance rates of 73% and 52%, respectively (Greenberg
1984). The precision of the estimate for the difference in
compliance between mono- and polytherapy treatment
groups was used as the basis for the sample size calcula-
tion. Based on the above assumptions and a sample of 960
patients, the 95% confidence interval (CI) width for a dif-
ference in such proportions is ±7.1. Missing data were not
imputed; all eligible patients were used for analyses. Due
to the observational design, primarily descriptive statistics
were used: means, standard deviations, and frequencies.
For the primary analysis of factors associated with
compliance, the categories of compliance (high, moder-
ate, low, and noncompliant) were dichotomized into ‘high’
compliance (≥80% compliance, corresponding to the high
compliance category) and ‘low’ compliance (<80% compli-
ance, a pooled group comprised of the moderate, low,
and noncompliance categories). This classification was
made as a result of the rare occurrence of low and non-
compliance ratings (see the Results section). Baseline
characteristics were compared between compliance levels
by the chi-square test for categorical variables and by
the t-test for continuous variables. Time to relapse was
plotted by the Kaplan-Meier approach. The generalized
estimating equations (GEE) approach was used to model
evaluations of compliance collected at multiple visits
during the study as a function of various baseline and
post-baseline (i.e., time-varying) covariates. Some patients
were prescribed a number of different drug regimens
during the 3- or 6-month intervals between study visits
and therefore had more than one compliance rating
recorded at the corresponding visits. In case of such
regimen changes between study visits, the lowest recorded
compliance level was used for analyses.
Patient characteristics were analyzed at each visit when
olanzapine-containing regimens were recorded. Due to
the low proportion of patients not receiving olanzapine
(proportions ranged from 2% to 11% between visits), they
were not summarized separately. Due to the high number
of baseline covariates collected in the study, only variables
different at baseline at a 10% significance level and vari-
ables thought to be influential (country effect, treatment
as mono- versus polytherapy) were entered into the initial
joint model for compliance and were then reduced using
stepwise procedures. At the next step, post-baseline values
for baseline variables selected by the stepwise procedure
were added to the model, and model reduction using step-
wise selection was applied.
Secondary analyses included similar GEE modeling with
repeated measures of total DAI-10 score over time and
quality of life over time (total EQ-5D score derived from
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independent variables suggested by clinicians: country,
education, olanzapine mono- versus polytherapy, inter-
action of treatment regimen by treatment duration, overall
CGI-S score, patient-physician relationship, patient insight
into their disease, indication of treatment for other psychi-
atric disorders, total EQ-5D score, EQ-5D VAS score,
compliance level, age, and gender. Similar models were
used to evaluate quality of life over time, measured by
total EQ-5D score derived from five domains and by
EQ-5D VAS score. Similar repeated measures logistic
regression modeling of compliance (GEE) was performed
with the ten sub-scores of the DAI-10 used as predictors.
Two analyses were performed to study the association of
compliance with relapse: logistic regression modeling
to look at the presence/absence of relapse and Cox
regression analysis to model the time to relapse. Because
of the significant differences in health-care systems of
the participating countries and different derivation of
the costs used in the study (psychiatric hospitalization
(with an overnight stay), outpatient consultations with
a psychiatrist, and day hospital or day care facility use),
UK 2007/2008 estimates of these costs were used in the
analyses. The relationship between total medical resource
utilization and total compliance over 2 years was modeled
using linear regression for total cost based on UK
estimates (also see the Results section) by baseline and
post-baseline compliance levels adjusted for significant
baseline variables, country, and treatment (mono/poly-
therapy and duration). Since compliance was of primary




As presented in the study flow diagram (Figure 1), 967
patients were enrolled in the study. Of these, 891 patients
were eligible to participate: 239 (26.8%) in Austria, 180
(20.2%) in Romania, 167 (18.7%) in Hungary, 145 (16.3%)
in Korea, 99 (11.1%) in Taiwan, and 61 (6.8%) in Mexico.
The most common reasons for noneligibility were sponsor
decision, age <18 years, CGI-S score >3, or no olanzapine
treatment before screening. A total of 657 patients (73.7%
of eligible patients) completed the 24-month study; the
most common reasons for discontinuation from the study
were lost to follow-up (11.1%), subject decision (7.0%),
and physician decision (5.5%).
Compliance level at baseline
In all countries, most patients were rated as being ‘highly
compliant,’ followed by ‘moderately compliant’; low and
noncompliant ratings constituted a very low proportion
at baseline. As presented in Table 1, the percentages of
patients receiving the different compliance level ratingswere not evenly distributed in the participating countries,
with the greatest proportion of high compliance ratings
found in Austria and in Korea and the lowest proportion
in Romania and in Taiwan. Low compliance ratings were
most frequently reported in Taiwan; the highest propor-
tion of noncompliance was recorded in Mexico.
Table 1 also shows the proportion of patients with
each compliance rating at baseline. The ‘high compliance
group’ (HCG; ≥80% compliance) comprised 594 patients
(66.7%), while the ‘low compliance group’ (LCG; <80%
compliance) comprised 297 patients (33.3%).
Baseline characteristics by level of compliance
Baseline characteristics are summarized in Table 2. There
were no significant differences regarding age, weight,
height, gender, and race between the HCG and LCG;
however, regarding functional and clinical characteristics,
the following significant differences were seen: compared
to patients in the LCG, patients in the HCG had a lower
mean CGI-S score, had a higher mean DAI-10 score, had
spent less time in hospital due to bipolar disorder in the
year before entering the study, had fewer relapses in the
last 4 weeks before study entry, had a higher mean EQ-5D
overall health status score, and had a higher mean EQ-5D
VAS score at baseline. Patients in the HCG also had
significantly more often participated in social activities
with friends or social groups, had higher level of work
activities, had less impairment in work activities, had a
better patient-physician relationship, had greater insight
into their illness, and had remained longer on an un-
changed treatment regimen before baseline. Psychiatric
comorbidities were reported very infrequently at baseline
and also throughout the study. Seventy-one percent of
patients in the HCG and 65% in the LCG (p = 0.065)
mentioned no comorbidity at all in the 4 weeks before
baseline. At the beginning of the study, 44.6% of patients
were treated with olanzapine monotherapy, while 55.4%
received olanzapine combination therapy (of those, 87.8%
in combination with a mood stabilizer).
Compliance and factors associated with compliance
during the study
Figure 2 shows the proportion of patients rated as being
‘highly’ and ‘moderately’ compliant at each visit during
the study (the proportion of patients showing low com-
pliance and noncompliance accounts for the remaining
percentages and is too low to be shown in the graph).
The proportion of patients rated as being ‘highly’ compliant
increased continuously from one visit to the next, from
67% at baseline to almost 80% at the last visit; conversely,
the proportion of patients rated as being ‘moderately’
compliant showed a steady decrease from 27% to 18%. This
shift could be associated with a higher discontinuation rate
in patients with lower compliance. No significant difference
Eligible
N=891






Violations of eligibility criteria:
Sponsor decision, age, CGI-S>3 or
no olanzapine taken
Most common reasons for 
discontinuation, N (%):
Lost to follow-up: 99 (11.1)
Subject decision: 62 (7.0)
Physician decision: 49 (5.5)
Figure 1 Patient disposition. CGI-S, Clinical Global Impression of Severity.
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olanzapine monotherapy and those taking olanzapine
in combination with other drugs.
Table 3 presents factors that were significantly associated
with compliance during the study. Compliance during the
study (modeled as a trend over time) was strongly related
to the baseline compliance rating, with patients who had a
high score at baseline having almost sevenfold higher odds
of being rated as ‘highly’ compliant during the study. There
was a strong variation in ratings between countries, with
patients in Mexico having four times higher odds of
receiving ‘high’ ratings than patients in Taiwan. Better
insight into illness was strongly associated with higher
levels of compliance, with an almost threefold increase in
the odds of high compliance from moderate to high
insight and a threefold decrease from moderate to low/
none. We found a nonlinear relationship between the
duration of the first treatment regimen and compliance,
in that the rate of compliance was higher for short
(≤30 days) and longer (>90 days) treatment regimens
than for treatment regimens lasting for 31 to 90 days
(p = 0.014). A lower number of inpatient days during
the 12 months prior to study entry was also associatedTable 1 Compliance level at baseline
Eligible at baseline High (≥80%) Moderate
Austria 239 (26.8) 187 (78.2) 43
Romania 180 (20.2) 89 (49.4) 78
Hungary 167 (18.7) 112 (67.1) 51
Korea 145 (16.3) 110 (75.9) 27
Taiwan 99 (11.1) 59 (59.6) 24
Mexico 61 (6.8) 37 (60.7) 18
Total 891 (100) 594 (66.7) 241
All data presented as n (%).with higher levels of compliance. Post-baseline variables
associated with high compliance were greater life satisfac-
tion and less work impairment during the study. There
was also an association with time, indicating increased
compliance from one visit to the next.
Symptoms and relapse during the study
Figure 3 indicates that the gap between the mean CGI-S
scores of patients in the HCG and LCG observed at
baseline did not diminish over the course of the study.
The mean CGI-S score of patients in the HCG remaining
in the study decreased throughout the course of the study,
whereas the CGI-S score of patients in the LCG was rela-
tively stable (no formal comparison over time was done).
Time to relapse was shorter in the LCG as illustrated in
Figure 4. After adjustment for other variables, less than
80% compliance at baseline was associated with a twofold
increase in the chance of relapse (Table 4), while a lower
CGI-S score during the study was associated with lower
odds of relapse. A difference of 1 unit (or 63% of the total
possible range) in the EQ-5D overall health status score
over time was associated with a fourfold decrease in
the odds of relapse. Patients with an ‘excellent’ patient-(60% to 79%) Low (20% to 59%) Noncompliant (<20%)
(18.0) 7 (2.9) 2 (0.8)
(43.3) 11 (6.1) 2 (1.1)
(30.5) 4 (2.4) 0
(18.6) 7 (4.8) 1 (0.7)
(24.2) 12 (12.1) 4 (4.0)
(29.5) 3 (4.9) 3 (4.9)
(27.0) 44 (4.9) 12 (1.3)








Age, years, mean (SD) 43.0 (12.8) 43.8 (12.9) 0.44
Weight, kg, mean (SD) 73.5 (13.8) 73.9 (14.1) 0.69
Height, cm, mean (SD) 168.1 (9.3) 167.1 (8.8) 0.11
Sex, females, n (%) 337 (56.7) 176 (59.3) 0.47
Race, n (%) 0.30
Caucasian 384 (65.1) 198 (67.3)
Hispanic 37 (6.3) 24 (8.2)
East Asian 169 (28.6) 72 (24.5)
Clinical characteristics
CGI-S, mean (SD) 2.4 (0.7) 2.6 (0.7) 0.002
DAI-10, mean (SD) 5.7 (3.7) 4.8 (4.0) 0.002
Days bipolar inpatient last year,
mean (SD)
15.4 (38.5) 18.4 (32.8) 0.029
Recent relapse, n (%) 68 (11.4) 68 (22.9) <0.001
Functional characteristics
EQ-5D overall health status
score (SD)
0.9 (0.2) 0.8 (0.2) 0.0012
EQ-5D VAS score (SD) 74.2 (15.4) 69.6 (17.6) <0.001
Number of activities with friends
or social groups, n (%)
0 100 (16.8) 85 (29.0)
1 66 (11.1) 40 (13.7) <0.001
2 117 (19.7) 49 (16.7)
3 78 (13.1) 40 (13.7)
4 70 (11.8) 20 (6.8)
≥5 163 (27.4) 59 (20.1)
Work activity, n (%)
Unable to work 34 (5.8) 26 (9.0) <0.001
Volunteer work 21 (3.6) 6 (2.1)
Student 34 (5.8) 12 (4.1)
Working for pay 199 (33.8) 76 (26.2)
Keeping house 109 (18.5) 48 (16.6)
Unemployed 59 (10.0) 23 (7.9)
Sheltered program 15 (2.5) 3 (1.0)
Retired 118 (20.0) 96 (33.1)
Impairment in work activities, n (%)
No impairment 123 (20.8) 39 (13.3)
Mild impairment 220 (37.2) 81 (27.6)
Moderate impairment 150 (25.4) 133 (45.2)
Severe impairment 50 (8.5) 22 (7.5)
Unable to work due to mental
illness
31 (5.2) 15 (5.1) <0.001
Table 2 Patient baseline characteristics by level of
compliance (Continued)
Patient-physician relationship, n (%)
Poor 0 7 (2.4) <0.001
Fair 20 (3.4) 25 (8.4)
Good 158 (26.6) 148 (49.8)
Very good 277 (46.6) 101 (34.0)
Excellent 139 (23.4) 16 (5.4)
Insight into illness, n (%)
None 3 (0.5) 3 (1.0)
Low 26 (4.4) 49 (16.5) <0.001
Medium 87 (14.6) 111 (37.4)
Moderate 168 (28.3) 93 (31.3)
High 310 (52.2) 41 (13.8)
Length of previous treatment
regimen (4 weeks before baseline,
containing olanzapine), n (%)
<14 days 8 (1.3) 10 (3.5)
15 to 30 days 125 (21.1) 91 (31.5) <0.001
31 to 90 days 212 (35.8) 77 (26.6)
>90 days 244 (41.1) 101 (34.9)
CGI-S, Clinical Global Impression of Severity; DAI-10, Drug Attitude Inventory -
short version; EQ-5D, European Quality of Life instrument-5 dimensions; SD,
standard deviation; VAS, visual analog scale.
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than patients with a ‘very good’ rating, and there was
high variability in reports of relapse between countries
(p < 0.001). Similarly, the time to relapse was different
between countries and a difference of 1 unit in the EQ-
5D overall health status score (the total EQ-5D range
was −0.59 to 1) was associated with a 54% reduction in
the hazard of relapse. No other baseline characteristics
were associated with time to relapse.Association of compliance with attitude towards
medication
To determine whether higher levels of compliance were
associated with a more affirmative attitude towards medica-
tion as measured by the DAI-10, single DAI-10 questions
and the total DAI-10 score were modeled versus compli-
ance at each visit. Answers to questions 1 (‘Good things
of the current medication outweighing the bad ’, odds ra-
tio (OR) = 2.24 [1.64, 3.04], p < 0.001), 2 (‘Feeling weird
on the current medication’, OR= 0.70 [0.55, 0.88], p = 0.003),
3 (‘Taking medication of own choice ’, OR = 1.34
[1.07, 1.67], p = 0.010), and 5 (‘Feeling tired and sluggish
on the current medication’, OR = 0.82 [0.68, 0.995],
Figure 2 Compliance during study (number and percentage of patients on olanzapine-containing regimens). ‘Compliance’ and
‘noncompliant’ patients were too low to be shown.
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model. Similarly, the total DAI-10 score (OR = 1.08
[1.05, 1.10], p < 0.001) turned out to be significantly
associated with compliance as a single predictor. The
model fit suggests that using the total DAI-10 score asTable 3 Factors associated with compliance during the study
Variables Value
Compliance at baseline Low (<80%)
High (80% to 100%)
Country
Length of initial treatment >90 days
31 to 90 days
30 days or fewer




Number of days the patient used day hospital
Satisfaction with life during study Very satisfied
Satisfied
Neither satisfied nor dissatisf
Dissatisfied
Very dissatisfied




Time of observation Per visit
CI, confidence interval.a single predictor of compliance is better than using a
more complex model with the four sub-domains described
earlier or the ten sub-domains of the scale.
As shown in Table 5, being older and having higher
EQ-5D overall health status scores during the study,Odds ratio 95% CI p value (vs reference) p value (overall)
1 Reference <0.001
6.91 [5.04, 9.46] <0.001
<0.001
1 Reference 0.014
0.74 [0.54, 1.03] 0.073
1.42 [0.89, 2.27] 0.14
1 Reference <0.001
0.33 [0.20, 0.56] <0.001
0.94 [0.65, 1.35] 0.73
2.79 [1.87, 4.18] <0.001
0.99 [0.98, 0.99] 0.002
1 Reference 0.002
0.65 [0.48, 0.88] 0.006
ied 0.56 [0.37, 0.83] 0.004
0.39 [0.24, 0.62] <0.001
0.81 [0.39, 1.67] 0.57
1 Reference 0.007
0.91 [0.53, 1.57] 0.75
1.15 [0.69, 1.92] 0.59
1.64 [0.92, 2.92] 0.09
0.013
Figure 3 Mean CGI-S score (±standard deviation (SD)) during the study by current compliance level. CGI-S, Clinical Global Impression of Severity.
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baseline insight into illness were identified as being posi-
tively associated with a more affirmative attitude towards
medication. Higher CGI-S scores during the study were as-
sociated with a less affirmative attitude towards medication,
and there were substantial differences in DAI-10 ratings be-
tween countries, which were adjusted for in the model.
Association of compliance with medical resource utilization
Based on UK estimates, a day of hospital stay costs about
twice as much (£219) as day hospital or day care use (£98)
or an outpatient consultation with a psychiatrist (0.5
h = £103.5). According to such a cost structure, the logistic
regression model indicated that high compliance was
marginally associated with lower total medical resource
utilization (−£122 [−252, +9] per 3 months, p = 0.067), with
a strong increase in costs per each unit of higher CGI-S
score (+£314, p < 0.001), and change in costs over time
(p= 0.001), with lower costs in the second year of the study.
Association of compliance with quality of life
According to the GEE model, high compliance was
associated with better quality of life as assessed by the
EQ-5D. The increase of 1 unit (63%) in the derivedFigure 4 Kaplan-Meier analysis of time to relapse.index score was associated with a twofold increase in
the odds of high compliance (OR = 2.2, 95% CI = [1.4,
3.5], p = 0.001) after adjustment for time trend. Similarly,
an increase of 1% on the EQ-5D VAS scale resulted in
a 1.2% increase in the odds of high compliance (95%
CI = [0.7, 1.8], p < 0.001). Figure 5 shows the trend of the
mean EQ-5D health status score and the mean EQ-5D
VAS score. On both graphs, the mean EQ-5D score of
patients in the HCG was higher than that of patients in
the LCG throughout the study. Mean EQ-5D scores
increased in both groups during the course of the study.
Gender
Possible differences regarding compliance between male
and female patients were analyzed in the present patient
sample, but no statistically significant differences were
found. Similarly, no correlations between gender and any
of the secondary outcome parameters (e.g., DAI-10 total
score, time to relapse, total medical resource utilization)
were found.
Weight gain
Collection of adverse event data was not an objective of the
study since patients were receiving multiple medications
Table 4 Factors significantly associated with the absence of relapse (logistic regression results)
Factor Value OR 95% CI p value
Compliance to treatment regimen at baseline High vs low 2.08 [1.30, 3.33] 0.002
CGI-S over time Per unit 0.29 [0.18, 0.46] <0.001
Country 6 countries <0.001
EQ-5D overall health status score over time Per unit 4.16 [1.57, 11.04] 0.004
Patient-physician relationship Very good 1 Reference
Excellent 0.48 [0.26, 0.91] 0.023
Good 1.34 [0.80, 2.24] 0.26
Poor 0.91 [0.35, 2.37] 0.84
CGI-S, Clinical Global Impression of Severity; CI, confidence interval; EQ-5D, European Quality of Life instrument-5 dimensions (overall score based on UK norms);
OR, odds ratio.
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the treating physicians. However, patients' weight was
measured at each visit. Analyses of patients while on
olanzapine-containing treatment regimens indicated that
weight at baseline and 24 months was similar in the HCG
and LCG, with an average weight gain of approximately
2 kg being observed over the 2 years of the study, both
in the HCG (mean weight at baseline 73.5 kg (standard
deviation (SD) 13.8), at the 24-month visit 75.4 kg (SD
13.8)) and the LCG (mean weight at baseline 73.9 kg
(SD 14.1), at the 24-month visit 75.8 kg (SD 12.9)).
Discussion
To our knowledge, the present study is the first large,
noninterventional clinical trial assessing compliance to
treatment as the main outcome parameter in patients
with bipolar disorder. According to our analysis and in
line with everyday clinical experience, patients with ‘high’
versus ‘low’ compliance showed significant differences in a
range of parameters assessed at baseline and throughout
the study. Due to the observational and naturalistic
study design, conclusions regarding causality between
compliance and other parameters cannot be derived.
The findings that high baseline compliance is a strong




EQ-5D (range −0.6 to 1)
EQ-5D VAS




Country (increasing order: Taiwan, Korea, Austria, Hungary, Mexico, Romania)
CGI-S, Clinical Global Impression of Severity; CI, confidence interval; EQ-5D, Europeapatients' attitude towards treatment suggest that com-
pliance might be a rather stable factor in the treatment
course of bipolar patients. It is also possible that the
strong association between baseline and 2-year compliance
may be due to both variables being secondary to one or
more common factors that remained relatively stable
during follow-up.
The interrelation between compliance and all other
investigated variables was multifaceted: high levels of
compliance at baseline and during the study were signifi-
cantly associated with more favorable clinical, functional,
and social outcomes in the HCG compared to the LCG,
suggesting that the relationship between compliance
and these factors may at least be bi-directional. While
higher levels of compliance may contribute to lower
CGI-S scores, better insight into illness, higher levels of
social and work performance, and better quality of life,
it may very well be that patients with more favorable
parameters at baseline (better clinical status, less severe
disease course, better disease insight, etc.) show higher
levels of compliance per se and that, in this context,
better compliance might be only one additional parameter
contributing to a more favorable prognosis. However, even
if causality between parameters cannot be determined,
improving some of these variables may also have a positivetive of better attitude towards medication
Estimate 95% CI p value
0.019 [0.004, 0.034] 0.012
−0.31 [−0.42, −0.20] <0.001
1.11 [0.56, 1.66] <0.001
0.02 [0.01, 0.02] <0.001
0 Reference
−1.66 [−2.37, −0.94] <0.001
−0.38 [−0.89, 0.13] 0.14
0.90 [0.43, 1.37] <0.001
0 to 3.86 <0.001
n Quality of Life instrument-5 dimensions; VAS, visual analog scale.
(A) 
(B) 
Figure 5 Mean (±SD) EQ-5D VAS score (A) and mean (±SD) EQ-5D health status score (B). EQ-5D, European Quality of Life instrument-5
dimensions; VAS, visual analog scale.
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thus allowing for other possible interventions (such as
psychoeducation, improvement of patient-physician rela-
tionship, etc.) besides pharmacological treatment in the
long-term management of bipolar disorder.
Overall, in our patient sample, compliance was high both
at baseline and also at all follow-up visits, regardless of
the use of olanzapine as monotherapy or in combination
with other agents. Compliance increased among study
completers, a finding that is not surprising, as ‘lost to
follow-up’ and ‘patient decision’, the main reasons for
dropout, could be interpreted as noncompliance to the
treatment schedule. Hence, the clinical trial setting itself
might be a confounder, since higher rates of compliance
are likely to occur in patients willing to participate in
clinical research. This suggestion is supported by the
results of a study of the effectiveness of lithium in bipo-
lar disorder, in which patients were highly compliant
with their treatment regimen (Sylvia et al. 2014). To
minimize this factor, a naturalistic study design was chosen
to investigate compliance under conditions that mimic
routine clinical care. In order to increase reliability and
generalizability, a large patient population was investigated,
and a follow-up period of 2 years was chosen to determine
the long-term disease course of this patient sample.Furthermore, as patients from different European countries
(including countries in both Western and Eastern Europe
with different health-care systems), Latin America, and
Asia were included in the study, results from different
social and medical practices regarding compliance could
be obtained.
Overall, 44% of the patients included in the present
study were on olanzapine monotherapy. This surprisingly
high proportion may be the result of selection bias due to
the clinical trial setting. However, the use of monotherapy
may also contribute to higher levels of compliance, as it is
easy for patients to use. While data on combination
therapy in the maintenance treatment of bipolar disorders
are limited, olanzapine monotherapy has been shown in
several studies to have an efficacy profile comparable to
that of lithium and was therefore rated as having Level A
evidence for the prophylactic treatment of bipolar patients
(Grunze et al. 2004). Additionally, only stable patients
who had received olanzapine treatment for at least 4 weeks
before baseline and who had CGI-S scores of ≤3 were
allowed to enter the trial, a constellation further contri-
buting to the high compliance rates observed in this
particular patient population. This agrees with the high
rate of completers in the study, while in routine clinical
practice, many patients have severe problems not only
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attending appointments (DelBello et al. 2007; Scott and
Pope 2002; Strakowski et al. 2007; Chen et al. 2013). In
line with that, compliance was evaluated regarding the
whole treatment regimen (medication, keeping appoint-
ments, etc.) in this trial and thus cannot be attributed
completely to only one particular aspect of treatment,
such as a single medication.
The rationale for including only patients who had been
stabilized with olanzapine given as mono- or combina-
tion therapy was that at the start of the study (January
2005), olanzapine was the only antipsychotic approved
for the treatment of bipolar disorder in the participating
countries. It is possible that the inclusion of patients
stabilized solely on olanzapine introduced bias into the
study (Lundh et al. 2012). However, a study by Rascati
et al. (2011) showed that bipolar patients taking olanzapine
were 35% more likely (p = 0.04) to discontinue their medi-
cation than patients taking ziprasidone, and another study
showed that compliance with quetiapine was marginally
greater (2% to 4% greater; p ≤ 0.002) than that with other
antipsychotics, including olanzapine (Gianfrancesco et al.
2006). Conversely, another study showed that compliance
among patients with bipolar disorder was similar for the
different atypical antipsychotics (Hassan et al. 2007).
Thus, it is unlikely that limiting patient participation to
those treated with olanzapine had a significant effect on
the results of the study. Furthermore, the recruitment of
such patients would have provided a consistent patient
population in terms of the basic treatment received.
Several other factors may also have contributed to the
high levels of compliance in our patient sample. Com-
pliance was assessed by a subjective measurement (a
physician-rated scale); however, clinicians tend to over-
estimate their patients' compliance rates to the prescribed
treatment regimen (Osterberg and Blaschke 2005). As
shown previously, there can be significant disagreement
between physicians' estimates of patients' compliance
and the results of pill counts or electronic monitoring
(Velligan et al. 2007). In the present study, higher levels
of compliance were once again shown to be associated
with lower probability for relapse; therefore, our findings
are in line with several other studies showing that com-
pliance may be an important factor in the long-term
management of bipolar disorder, especially with regard
to relapse prevention and rehospitalization (Velligan et al.
2009; Novick et al. 2010).
In our study, compliance showed a nonlinear relation-
ship with the duration of treatment at the first routine
follow-up visit (approximately 3 months post baseline).
This could have been related to the fact that it is easier
to be compliant in the short term and to the presence
of a group of patients who are highly compliant and
therefore likely to continue taking their medication formore than 3 months. In addition, there is potential for
the taking of medication to become a habit in the longer
term. Alternatively, it could have been due to an artifact
in the study design in that patients were treated with
olanzapine for at least 4 weeks before study entry, yet
those who discontinued treatment by the first follow-up
visit would be categorized as having a treatment duration
of 31 to 90 days rather than >90 days. Further research is
needed to explore the change in compliance with long-
term treatment.
Despite substantial advances in pharmacological and
nonpharmacological treatment possibilities, bipolar dis-
order often entails multiple relapses and impaired psy-
chological functioning (Berk et al. 2010; Solomon et al.
2010). However, the extent to which modern treatments
have influenced the natural course of mental disorders is
not entirely clear. Providing a prognosis of the course and
outcome of bipolar disorder(s) continues to be challen-
ging, despite the variety of treatment options and multiple
research efforts worldwide. Although long-term symptom-
atic remission does not guarantee functional recovery, it
may have a favorable impact on long-term overall progno-
sis. The high degree of treatment resistance in patients
with bipolar disorder highlights the need to develop better
outcome predictors for compliance, prognosis, and treat-
ment intervention, designed to reverse or prevent this
burden of illness (Treuer and Tohen 2010). Therefore,
some of our findings, such as differences in compliance
rates between countries, as well as potential cultural
influences and the influence of different health-care
systems - factors that may influence the compliance of
bipolar patients - need further investigation.
Other factors crucial for compliance, such as adverse
events during treatment with antipsychotics/mood stabi-
lizers and their impact on patients' compliance could
only be evaluated to a very limited extent (and not in
context with a single medication) in the present study,
as combination therapy, concomitant medications, and
changes in treatment regimens were allowed at all
time-points during study participation. Overall weight
gain was low in our olanzapine-treated patient sample,
another factor that might have contributed to the high
compliance rates in study completers. However, weight
gain at the individual patient level showed much vari-
ability. Analyses of patients on olanzapine-containing
regimens in the present study indicated less weight gain
during the course of the trial compared to other studies
(Lipkovich et al. 2006) and may be driven by dropouts due
to weight gain. Furthermore, comorbidities and personal-
ity traits (Axelsson et al. 2009; Halimi et al. 2010; Holma
et al. 2010; Jerant et al. 2011; Pappa et al. 2006; Pompili
et al. 2013) - both also very likely contributing to different
levels of compliance in bipolar patients - were not system-
atically assessed by structured interviews. Therefore, and
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reported in our sample and are not in accordance with
published comorbidity rates in bipolar patients (especially
alcohol/substance abuse, personality disorders, comorbid
attention deficit hyperactivity disorder, etc.) (Correa et al.
2010; DelBello et al. 2007; Perugi et al. 2010).
One limitation of our study is the fact that no specific
diagnostic instruments were used to screen for bipolar
disorder. Rather, physicians were requested to establish
the diagnosis according to their routine clinical approach.
This is an acceptable approach given the observational
nature of the study, but it is worth noting that inter-rater
reliability for diagnosing bipolar I and II disorders was low
in initial field trials of the fifth edition of the Diagnostic
and Statistical Manual of Mental Disorders (kappa values
0.56 and 0.40, respectively) (Freedman et al. 2013).
Another limitation is the fact that inter-rater reliability
for the different ad hoc questionnaires used to measure
outcomes was not evaluated because, although important
for controlled clinical trials, this type of evaluation is not
generally used in naturalistic studies. The reason for this
is that the key goal of these studies is to investigate how
such rating is performed in a ‘real world’ setting. In
addition, investigators did not receive specific training for
using the ad hoc questionnaires because they involved
simple questions with a number of possible answers and
were therefore very easy to administer.
Other limitations include the fact that compliance was
measured by a subjective rather than objective approach
(e.g., measurement of plasma olanzapine levels, pill counts,
or electronic monitoring). As discussed above, physicians
tend to overestimate patient compliance, whichmay account
for the high levels of compliance observed in the study.
Nevertheless, our findings are in line with several other stud-
ies showing that compliance may be an important factor in
the long-termmanagement of bipolar disorder. Additionally,
although compliance results from different social and med-
ical practices were obtained in our study due to the inclusion
of patients from different countries, no statistical analyses by
country were performed because such analyses would have
been very limited, particularly with so much variability in the
data. A final limitation is the lack of investigation of the effect
of symptomatology on compliance. Patients who are more
symptomatic often change medication frequently because
they feel it is not effective, and this can cause them to be less
compliant with their current treatment regimen. The effect
of the degree of symptomatology on compliance warrants
further investigation.
Conclusions
Compliance is one of the key factors in the successful
management and long-term treatment of patients with
bipolar disorder. Therefore, it should be the subject of
further investigation as the main outcome parameter ofclinical studies. Factors that have been shown to positively in-
fluence compliance, such as the patient-physician relation-
ship, should be given more attention in the management of
bipolar patients.
Abbreviations
CGI-S: Clinical Global Impression of Severity; CI: confidence interval; DAI-10: Drug
Attitude Inventory - short version; EQ-5D: European Quality of Life instrument-5
dimensions; GEE: generalized estimating equations; HCG: high compliance group;
LCG: low compliance group; OR: odds ratio; SD: standard deviation; VAS: visual
analog scale.
Competing interests
Chih-Ken Chen, Ágnes Fábián, María Gloria Pujol-Luna, Young-chul Shin, and
Siegfried Kasper disclose research grants for their institutions from Eli Lilly
and Company for conducting the study.
Chih-Ken Chen discloses board membership and consultancy (and lecturer)
for AstraZeneca, GlaxoSmithKline, MSD, Otsuka, Lundbeck, and Sanofi-Aventis
in Taiwan.
Siegfried Kasper discloses board membership, consultancy, and expert
testimony for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Pfizer,
Janssen Pharmaceuticals, Sepracor, Servier, Pierre Fabre, Wyeth, MSD, and
Schwabe; payment for lectures, including serving on speakers bureaus, for
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Janssen Pharmaceuticals,
Pierre Fabre, Organon, CSC, Servier, Pfizer, and GlaxoSmithKline; travel/
accommodation/meeting expenses unrelated to activities listed from
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Janssen Pharmaceuticals,
Pierre Fabre, Organon, CSC, Servier, Pfizer, and GlaxoSmithKline; and grants/
pending grants for his institution from AstraZeneca, Eli Lilly, Lundbeck,
Bristol-Myers Squibb, Sepracor, Servier, Novartis, and Pfizer.
Alexandra Kutzelnigg discloses support for her institution for travel to
meetings for the study or other purposes (travel expenses to the IRBD,
International Review of Bipolar Disorders - Congress of the European Bipolar
Forum, May 2010, Budapest) and payment for lectures, including serving on
speakers bureaus, for Eli Lilly, Novartis, and Affiris AG and has acted as a
consultant for Eli Lilly, Biogen Idec, and Affiris AG.
Martin Kopeinig is a former employee of Eli Lilly and Company.
Tamás Treuer, Yulia D'yachkova, Claudia Deix, and Dagmar Doby are
employees of Eli Lilly and Company.
Authors' contributions
DD and TT designed the study protocol. AK and CD drafted the manuscript.
All authors were involved in the analysis and interpretation of data and have
critically reviewed the manuscript for important intellectual content. All
authors were involved in the decision to submit the manuscript for
publication and have read and approved the final manuscript.
Acknowledgements
We would like to express our gratitude to all participating patients and
investigators.
This study (F1D-OE-B015) was funded by Eli Lilly and Company.
Author details
1Department of Psychiatry and Psychotherapy, Division of Biological
Psychiatry, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna,
Austria. 2Psychosoziale Dienste in Wien (PSD), Mariahilfer Strasse 77-79, 1060
Vienna, Austria. 3Chang Gung Memorial Hospital, Keelung, Chang Gung
University School of Medicine, No.200 Lane 208, Ji-Jin 1st Road, Anle District,
Keelung City, 204 Taoyuan, Taiwan. 4Réthy Pál Kórház-Rendelőintézet,
Békéscsaba, Hungary. 5Hosp. Angeles Metropolitano, 59-600 Roma Sur, 06760
Mexico City, Mexico. 6Kangbuk Samsung Hospital, 110-746, Seoul, South
Korea. 7Eli Lilly, Madách u. 13-14. (VII. emelet), 1075 Budapest, Hungary. 8Eli
Lilly, Kölblgasse 8-10, 1030 Vienna, Austria.
Received: 17 February 2014 Accepted: 1 October 2014
References
Adams J, Scott J (2000) Predicting medication adherence in severe mental
disorders. Acta Psychiatr Scand 101:119–124
Kutzelnigg et al. International Journal of Bipolar Disorders 2014, 2:13 Page 13 of 14
http://www.journalbipolardisorders.com/content/2/1/13Awad GA (1993) Subjective response to neuroleptics in schizophrenia. Schizophr
Bull 19:609–618
Axelsson M, Emilsson M, Brink E, Lundgren J, Toren K, Lötvall J (2009) Personality,
adherence, asthma control and health-related quality of life in young adult
asthmatics. Respir Med 103:1033–1040
Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL (2003) Effectiveness of rapid initial
dose escalation of up to forty milligrams per day of oral olanzapine in acute
agitation. J Clin Psychopharmacol 23:342–348
Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C, Yucel M, Pantelis C,
Murphy B, Vieta E, Dodd S, McGorry PD (2010) Evidence and implications for
early intervention in bipolar disorder. J Ment Health 19:113–126
Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR (2009) Pharmacological
interventions for the prevention of relapse in bipolar disorder: a systematic
review of controlled trials. J Psychopharmacol 23:574–591
Chen W, Deveaugh-Geiss AM, Palmer L, Princic N, Chen YT (2013) Patterns of
atypical antipsychotic therapy use in adults with bipolar I disorder in the
USA. Hum Psychopharmacol 28:428–437
Colom F, Vieta E (2004) Improving the outcome of bipolar disorder through
non-pharmacological strategies: the role of psychoeducation. Rev Bras
Psiquiatr 26(Suppl 3):47–50
Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S (2010) Is
unrecognized bipolar disorder a frequent contributor to apparent treatment
resistant depression? J Affect Disord 127(1-3):10–18
Cramer J, Rosenheck R (1998) Compliance with medication regimens for mental
and physical disorders. Psychiatr Serv 49:196–201
Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, VA Naltrexone Study Group 425
(2003) Medication compliance feedback and monitoring in a clinical trial:
predictors and outcomes. Value Health 6:566–573
DelBello M, Hanserman D, Adler CM, Fleck DE, Strakowski SM (2007) Twelve-month
outcome of adolescents with bipolar disorder following first hospitalization for
manic or mixed episode. Am J Psychiatry 164:582–590
Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Gabbard GO,
Gau SS, Javitt DC, Oquendo MA, Shrout PE, Vieta E, Yager J (2013) The initial
field trials of DSM-5: new blooms and old thorns. Am J Psychiatry 170:1–5
Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH (2006) Treatment
adherence among patients with bipolar or manic disorder taking atypical
and typical antipsychotics. J Clin Psychiatry 67:222–232
Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, Baldessarini RJ
(2006) Suicidal risk in bipolar I disorder patients and adherence to long-term
lithium treatment. Bipolar Disord 8:618–624
Goodwin GM, for the Consensus Group of the British Association for
Psychopharmacology (2003) Evidence-based guidelines for treating
bipolar disorder: recommendations from the British Association for
Psychopharmacology. J Psychopharmacol 17:149–173
Goodwin GM, for the Consensus Group of the British Association for
Psychopharmacology (2009) Evidence-based guidelines for treating bipolar
disorder: revised second edition—recommendations from the British
Association for Psychopharmacology. J Psychopharmacol 23:346–388
Greenberg RN (1984) Overview of patient compliance with medication dosing:
a literature review. Clin Ther 5:192–199
Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ, WFSBP Task Force on Treatment
Guidelines for Bipolar Disorders (2004) The World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar
disorders, part III: maintenance treatment. Word J Biol Psychiatry 5:120–135
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP
Task Force on Treatment Guidelines for Bipolar Disorders (2009) The World
Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
biological treatment of bipolar disorders: update 2009 on the treatment of
acute mania. World J Biol Psychiatry 10:85–116
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP
Task Force on Treatment Guidelines for Bipolar Disorders (2010) The World
Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
biological treatment of bipolar disorders: update 2010 on the treatment of
acute bipolar depression. World J Biol Psychiatry 11:81–109
Guy W (1976) Clinical global impressions. In: ECDEU assessment manual for
psychopharmacology, revised. National Institute of Mental Health, Rockville
Halimi L, Pry R, Pithon G, Godard P, Varrin M, Chanez P (2010) Severe asthma and
adherence to peak flow monitoring: longitudinal assessment of
psychological aspects. J Psychosom Res 69:331–340
Hassan M, Madhavan SS, Kalsekar ID, Makela EH, Rajagopalan K, Islam S,
Kavookjian J, Miller LA (2007) Comparing adherence to and persistence withantipsychotic therapy among patients with bipolar disorder. Ann
Pharmacother 41:1812–1818
Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed
treatment: clinical applications. JAMA 288:2880–2883
Hirschfield RMA (2014) Guideline watch: practice guideline for the treatment
of patients with bipolar disorder, 2nd edn., Psychiatryonline. http://
psychiatryonline.org/content.aspx?bookid=28&sectionid=1682557.
Accessed 23 May 2014
Holma IA, Holma KM, Melartin TK, Isometsä ET (2010) Treatment attitudes and
adherence of psychiatric patients with major depressive disorder: a five-year
prospective study. J Affect Disord 127(1-3):102–112
Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly
patients with and without acute coronary syndromes. JAMA 288:462–467
Jerant A, Chapman B, Duberstein P, Robbins J, Franks P (2011) Personality and
medication non-adherence among older adults enrolled in a six-year trial.
Br J Health Psychol 16:151–169
Judd LL, Akiskal HS (2003) The prevalence and disability of bipolar spectrum
disorders in the US population: re-analysis of the ECA database taking into
account subthreshold cases. J Affect Disord 73:123–131
Li C, Chen C, Qiu B, Yang G (2014) A 2-year follow-up study of discharged
psychiatric patients with bipolar disorder. Psychiatry Res 218:75–78
Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, Hardy T (2006)
Early Predictors of substantial weight gain in bipolar patients treated with
olanzapine. J Clin Psychopharmacol 26:316–320
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship
and research outcome. Cochrane Database Syst Rev 12:MR000033
Murray CJ, Lopez AD (1996) Evidence-based health policy-lessons from the Global
Burden of Disease Study. Science 274:740–743
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM (2010)
Predictors and clinical consequences of non-adherence with antipsychotic
medication in the outpatient treatment of schizophrenia. Psychiatry Res
176:109–113.
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497
Pappa C, Hyphantis T, Pappa S, Aspiotis M, Stefaniotou M, Kitsos G, Psilas K,
Mavreas V (2006) Psychiatric manifestations and personality traits associated
with glaucoma treatment. J Psychsom Res 61:609–617
Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS (2010) Adjunctive
valproate in panic disorder patients with comorbid bipolar disorder or
otherwise resistant to standard antidepressants: a 3-year “open” follow-up
study. Eur Arch Psychiatry Clin Neurosci 260:553–560
Pompili M, Venturini P, Palermo M, Stefani H, Seretti ME, Lamis DA, Serafini G, Amore M,
Girardi P (2013) Mood disorders medications: predictors of nonadherence - review
of the current literature. Expert Rev Neurother 13:809–825
Rascati KL, Richards KM, Ott CA, Goddard AW, Stafkey-Mailey D, Alvir J, Sanders KN,
Mychaskiw M (2011) Adherence, persistence of use, and costs associated with
second-generation antipsychotics for bipolar disorder. Psychiatr Serv 62:1032–1040
Regeer EJ, ten Have M, Rosso ML, Hakkaart-van Roijen L, Vollebergh W, Nolen WA
(2004) Prevalence of bipolar disorder in the general population: a reappraisal
study of the Netherlands Mental Health Survey and Incidence Study. Acta
Psychiatr Scand 110:374–382
Scott J, Pope M (2002) Non-adherence with mood stabilizers: prevalence and
predictors. J Clin Psychiatry 63:384–390
Sharma PS, Kongasseri S, Praharaj SK (2014) Outcome of mood stabilizer
discontinuation in bipolar disorder after 5 years of euthymia. J Clin
Psychopharmacol 34:504–507
Simhandl C, König B, Amann BL (2014) A prospective 4-year naturalistic follow-up
of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry
75:254–262
Solomon DA, Leon AC, Coryell WH, Endicott J, Li C, Fiedorowicz JG, Boyken L,
Keller MB (2010) Longitudinal course of bipolar I disorder: duration of mood
episodes. Arch Gen Psychiatry 67:339–347
Strakowski SM, Tsai SY, DelBello MP, Chen CC, Fleck DE, Adler CM, Arndt S,
Amicone J (2007) Outcome following a first manic episode: cross-national
U.S. and Taiwan comparison. Bipolar Disord 9:820–827
Sun SX, Liu GG, Christensen DB, Fu AZ (2007) Review and analysis of hospitalization
costs associated with antipsychotic nonadherence in the treatment of
schizophrenia in the United States. Curr Med Res Opin 10:2305–2312
Sylvia LG, Reilly-Harrington NA, Leon AC, Kansky CI, Calabrese JR, Bowden CL, Ketter TA,
Friedman ES, Iosifescu DV, Thase ME, Ostacher MJ, Keyes M, Rabideau D,
Nierenberg AA (2014) Medication adherence in a comparative effectiveness trial
for bipolar disorder. Acta Psychiatr Scand 129:359–365
Kutzelnigg et al. International Journal of Bipolar Disorders 2014, 2:13 Page 14 of 14
http://www.journalbipolardisorders.com/content/2/1/13The EuroQol Group (1990) EuroQol–a new facility for the measurement of
health-related quality of life. Health Policy 16:199–208
Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F,
Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V
(1999) Olanzapine versus placebo in the treatment of acute mania. Olanzapine
HGEH Study Group. Am J Psychiatry 156:702–709
Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs
GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD,
Breier A (2002) Efficacy of olanzapine in combination with valproate or
lithium in the treatment of mania in patients partially nonresponsive to
valproate or lithium monotherapy. Arch Gen Psychiatry 59:62–69
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB,
Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD,
Breier A (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination
in the treatment of bipolar I depression. Arch Gen Psychiatry.
60:1079-88. Erratum in. Arch Gen Psychiatry 2004, 61:176
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM,
Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R,
Baker RW, Crane H, Dossenbach MR, Bowden CL (2005) Olanzapine versus
lithium in the maintenance treatment of bipolar disorder: a 12-month,
randomized, double-blind, controlled clinical trial. Am J Psychiatry
162:1281–1290
Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou
JC, Bowden CL (2006) Randomized, placebo-controlled trial of olanzapine as
maintenance therapy in patients with bipolar I disorder responding to acute
treatment with olanzapine. Am J Psychiatry 163:247–256
Treuer T, Tohen M (2010) Predicting the course and outcome of bipolar disorder:
a review. Eur Psychiatry 25:328–333
Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW,
Ereshefsky L, Miller AL (2007) Relationships among subjective and objective
measures of adherence to oral antipsychotic medications. Psychiatr Serv
58:1187–1192
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP (2009)
The expert consensus guideline series: adherence problems in patients with
serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1–46
Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS,
Sharma V, Beaulieu S, Guidelines Group, CANMAT (2006) Canadian Network
for Mood and Anxiety Treatments (CANMAT) guidelines for the management
of patients with bipolar disorder: update 2007. Bipolar Disord 8:721–739
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C,
MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond
DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and
International Society for Bipolar Disorders (ISBD) collaborative update of
CANMAT guidelines for the management of patients with bipolar disorder:
update 2013. Bipolar Disord 15:1–44
Zygmunt A, Olfson M, Boyer CA, Mechanic D (2002) Interventions to improve
medication adherence in schizophrenia. Am J Psychiatry 159:1653–1664
doi:10.1186/s40345-014-0013-x
Cite this article as: Kutzelnigg et al.: Compliance as a stable function in
the treatment course of bipolar disorder in patients stabilized on
olanzapine: results from a 24-month observational study. International
Journal of Bipolar Disorders 2014 2:13.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
